Main > ONCOLOGY (**) > Skin Cancer>Melanoma>MET *** > Treatment > Co: USA. B. NivoluMAb+IpilimuMAb***
Co: USA. B. NivoluMAb+IpilimuMAb***'s subsections
(*) CA Approval Date: 2016. 10.31.
(*) EU Approval Date: 2016. 05.11.
(*) USA Approval Date: 2015. 10.01
Company
Patent>Assignee; Claims; No.; Etc.
Patent>Total USA No.: 5
Patent>UpDate: 2020. 02.18.
PR Web-Site (EU Approval)
TradeMark
TradeMark Web-Site
Co: USA. B. NivoluMAb+IpilimuMAb***'s products
This section has no products